Shopping Cart
- Remove All
- Your shopping cart is currently empty
ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $52 | In Stock | |
5 mg | $123 | In Stock | |
10 mg | $198 | In Stock | |
25 mg | $372 | In Stock | |
50 mg | $596 | In Stock | |
100 mg | $953 | In Stock | |
1 mL x 10 mM (in DMSO) | $135 | In Stock |
Description | ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 and inhibits the cleavage of Notch protein. |
Targets&IC50 | ADAM17:31.6 μM , Tyrosine phosphatase:, Tyrosine phosphatase:(ki)26.22 μM |
In vitro | ZLDI-8;?it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.?ZLDI-8 treatment enhanced the susceptibility of HCC cells to a small molecular kinase inhibitor Sorafenib, and chemotherapy agents Etoposide and Paclitaxel.?ZLDI-8 treatment enhanced the effect of Sorafenib on inhibiting tumor growth in nude HCC-bearing mice model[1]. |
In vivo | In nude HCC-bearing mice model, ZLDI-8 (0.2-2 mg/kg; intraperitoneal injection; every two days; for 20 days; nude mice) treatment enhances the effect of Sorafenib on inhibiting tumor growth [1]. |
Molecular Weight | 433.52 |
Formula | C24H23N3O3S |
Cas No. | 667880-38-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 62.5 mg/mL (144.17 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.